Jefferies Financial Group Inc. Invests $65.08 Million in iShares Biotechnology ETF $IBB

Jefferies Financial Group Inc. acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 450,807 shares of the financial services provider’s stock, valued at approximately $65,083,000. iShares Biotechnology ETF makes up approximately 0.3% of Jefferies Financial Group Inc.’s portfolio, making the stock its 20th largest holding.

Other hedge funds and other institutional investors have also modified their holdings of the company. Citigroup Inc. raised its holdings in iShares Biotechnology ETF by 27.0% during the second quarter. Citigroup Inc. now owns 4,073,967 shares of the financial services provider’s stock worth $515,398,000 after acquiring an additional 865,823 shares in the last quarter. JPMorgan Chase & Co. grew its stake in iShares Biotechnology ETF by 27.2% in the third quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock valued at $153,039,000 after purchasing an additional 226,852 shares in the last quarter. Barclays PLC grew its stake in iShares Biotechnology ETF by 6.7% in the third quarter. Barclays PLC now owns 416,191 shares of the financial services provider’s stock valued at $60,085,000 after purchasing an additional 26,032 shares in the last quarter. Bronte Capital Management Pty Ltd. increased its position in shares of iShares Biotechnology ETF by 12.6% during the 2nd quarter. Bronte Capital Management Pty Ltd. now owns 295,346 shares of the financial services provider’s stock worth $37,000 after purchasing an additional 32,947 shares during the last quarter. Finally, Employees Retirement System of Texas acquired a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth approximately $25,049,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 0.7%

Shares of iShares Biotechnology ETF stock opened at $167.56 on Monday. iShares Biotechnology ETF has a 12-month low of $107.43 and a 12-month high of $179.64. The business’s 50 day moving average is $172.68 and its 200-day moving average is $161.63.

iShares Biotechnology ETF Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, December 19th. Investors of record on Tuesday, December 16th were paid a $0.1831 dividend. This is a boost from iShares Biotechnology ETF’s previous quarterly dividend of $0.08. This represents a $0.73 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Tuesday, December 16th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.